AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
07. Juni 2021 07:00 ET
|
AzurRx BioPharma, Inc.
“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline trial data expected in Q1 2022 BOCA RATON, Fla., June 07, 2021 (GLOBE NEWSWIRE) -- AzurRx...
AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
06. April 2021 07:00 ET
|
AzurRx BioPharma, Inc.
“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline data expected in Q1 2022 DELRAY BEACH, Fla., April 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma,...